Methylation of tumor suppressor genes in a novel panel predicts clinical outcome in paraffin-embedded bladder tumors

Tumor Biology

Volumn 35, Issue 6, 2014, Pages 5777-5786

  García Baquero, Rodrigo ^a,b   Puerta, Patricia ^a   Beltran, Manuel ^b   Alvarez Mújica, Miguel ^c   Alvarez Ossorio, Jose Luis ^b   Sánchez Carbayo, Marta ^a  

^a CIC BIOGUNE   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Biomarker; Bladder cancer; DNA methylation; MS MLPA; Tissue

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER TUMOR; BNIP3 GENE; CACNA1A GENE; CACNA1G GENE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CCND2 GENE; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DLC1 GENE; DNA METHYLATION; FEMALE; H2AFX GENE; HISTOPATHOLOGY; HLTF GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; ID4 GENE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRDM2 GENE; PRIORITY JOURNAL; RUNX3 GENE; SFRP4 GENE; SFRP5 GENE; TGIF GENE; TIMP3 GENE; TUMOR SUPPRESSOR GENE; TWIST1 GENE;

ADULT; AGED; DNA METHYLATION; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED; PARAFFIN EMBEDDING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; URINARY BLADDER NEOPLASMS;

EID: 84904759754     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1767-6     Document Type: Article

References (30)

1. Wolff EM, Liang G, Jones PA. Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol. 2005;2:502-10. (Pubitemid 41594404)
2. Sanchez-Carbayo M. Hypermethylation in bladder cancer: biological pathways and translational applications. Tumor Biol. 2005;33:347-61.
3. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002;21:5427-40. (Pubitemid 34983479)
4. Sánchez-Carbayo M. Urine epigenomics: a promising path for bladder cancer diagnostics. Exp Rev Mol Diagn. 2012;5:429-32.
5. Aleman A, Adrien L, Lopez-Serra L, Cordon-Cardo C, Esteller M, Belbin TJ, et al. Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br J Cancer. 2008;98:466-73. (Pubitemid 351161244)
6. Nygren AO, Ameziane N, Duarte HM, Vijzelaar RN, Waisfisz Q, Hess CJ, et al. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 2005;33:e128.
7. Serizawa RR, Ralfkiaer U, Dahl C, Lam GW, Hansen AB, Steven K, et al. Custom-designed MLPA using multiple short synthetic probes: application to methylation analysis of five promoter CpG islands in tumor and urine specimens from patients with bladder cancer. J Mol Diagn. 2010;12:402-8.
8. Cabello MJ, Grau L, Franco N, Orenes E, Alvarez M, Blanca A, et al. Multiplexed methylation profiles of TSGs in bladder cancer. J Mol Diagn. 2011;13:29-40.
9. Zuiverloon TC, Beukers W, van der Keur KA, Munoz JR, Bangma CH, Lingsma HF, et al. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. BJU Int. 2012;109:941-8.
10. Agundez M, Grau L, Palou J, Algaba F, Villavicencio H, Sanchez-Carbayo M. Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours. Eur Urol. 2011;60:131-40.
11. Castro M, Grau L, Puerta P, Gimenez L, Venditti J, Quadrelli S, et al. Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med. 2010;8:86.
12. García-Baquero R, Puerta P, Beltran M, Alvarez M, Sacristan R, Alvarez-Ossorio JL, et al. Methylation of a novel panel of tumor suppressor genes in urine moves forward noninvasive diagnosis and prognosis of bladder cancer: a 2-center prospective study. J Urol. 2013;190:723-30.
13. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66:4-34. (Pubitemid 43049607)
14. Kim WJ, Kim EJ, Jeong P, Quan C, Kim J, Li QL, et al. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res. 2005;65:9347-54. (Pubitemid 41508002)
15. Yu J, Zhu T, Wang Z, Zhang H, Qian Z, Xu H, et al. A novel set of DNA methylation makers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res. 2007;13:7296-304.
16. Wolff EM, Liang G, Cortez CC, Tsai YC, Castelao JE, Cortessis VK, et al. RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking. Cancer Res. 2008;68:6208-14.
17. Kim EJ, Kim YJ, Jeong P, Ha YS, Bae SC, Kim WJ. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol. 2008;108:1141-5.
18. Renard I, Joniau S, van Cleynenbreugel B, Collette C, Naômé C, Vlassenbroeck I, et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur Urol. 2010;58:96-104.
19. Suzuki M, Shigematsu H, Shames DS, Sunaga N, Takahashi T, Shivapurkar N, et al. DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br J Cancer. 2005;93:1029-37. (Pubitemid 41548398)
20. Dhawan D, Hamdy FC, Rehman I, Patterson J, Cross SS, Feeley KM, et al. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol. 2006;209:336-43. (Pubitemid 43997742)
21. Hoque MO, Begum S, Brait M, Jeronimo C, Zahurak M, Ostrow KL, et al. TIMP3 promoter methylation is an independent prognostic factor for bladder cancer. J Urol. 2008;179:743-7.
22. Jarmalaite S, Andrekute R, Scesnaite A, Suziedelis K, Husgafvel-Pursiainen K, Jankevicius F. Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study. J Cancer Res Clin Oncol. 2010;136:847-54.
23. Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA, et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res. 2007;13:2046-53. (Pubitemid 46649871)
24. Shigematsu H, Suzuki M, Takahashi T, Miyajima K, Toyooka S, Shivapurkar N, et al. Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies. Int J Cancer. 2005;113:600-4. (Pubitemid 40038736)
25. Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt L, Ramanathan R, Hansen TB, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer. 2010;6:1327-34.
26. Marsit CJ, Karagas MR, Andrew A, Liu M, Danaee H, Schned AR, et al. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res. 2005;65:7081-5. (Pubitemid 41161235)
27. Urakami S, Shiina H, Enokida H, Kawakami T, Kawamoto K, Hirata H, et al. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res. 2006;12:2109-16.
28. Pu RT, Laitala LE, Clark DP. Methylation profiling of urothelial carcinoma in bladder biopsy and urine. Acta Cytol. 2006;50:499-506. (Pubitemid 44449614)
29. Brait M, Begum S, Carvalho AL, Dasgupta S, Vettore AL, Czerniak B, et al. Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2008;10:2786-94.
30. Friedrich MG, Chandrasoma S, Siegmund KD, Weisenberger DJ, Cheng JC, Toma MI, et al. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer. 2005;41:2769-78. (Pubitemid 41607571)